[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lung-metastases-from-any-primary\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lung-metastases-from-any-primary":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100490898","phase-2-phase-ii-trial-of-lung-chemoemobolization-100490898",false,"NCT05672108","Phase II Trial of Lung Chemoemobolization","Inclusion Criteria:\n\n* Lung cancer or lung metastases, with lung, endobronchial, pleural, or mediastinal tumors that are progressing on systemic therapy (or the patient cannot tolerate systemic therapy), and that are not amenable to resection, thermal ablation, or ablative radiation therapy\n* Lung-dominant disease (majority of active tumor volume is in the chest)\n* At least 18 years old\n\nExclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status \\> 2\n* Oxygen saturation \\< 92% on room air\n* Forced expiratory volume in 1 second (FEV1) \\< 60%\n* No measurable treatable disease, per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (for example, unable to measure tumor size on CT, or lung nodules are all \\< 1 cm)\n* Life expectancy \\< 6 months\n* Pulmonary hypertension (diagnosed or suspected on echocardiography, CT, magnetic resonance imaging \\[MRI\\], or direct pressure measurement)\n* Recent pulmonary embolism (within 3 months)\n* Pulmonary arteriovenous malformation\n* Active lung infection (pneumonia, empyema, or lung abscess requiring therapy within 1 month)\n* Symptomatic heart failure (American College of Cardiology \\[ACC\\]\u002FAmerican Heart Association \\[AHA\\] stage C or D)\n* Left bundle branch block (contraindication to pulmonary angiography)\n* Renal failure (estimated glomerular filtration rate \\[eGFR\\] \\< 30 mL\u002Fmin\u002F1.73 m\\^2)\n* Pregnancy or intent to become pregnant\n* Breast feeding\n* Altered mental status that would interfere with consent or follow-up\n* Platelets \\< 50,000 (after transfusion, if needed)\n* International normalized ratio (INR) \\> 2 (after transfusion, if needed)\n* Hemoglobin \\< 7 (after transfusion, if needed)\n* Hyperthyroidism or history of hyperthyroidism, including subclinical hyperthyroidism (contraindication to lipiodol)\n* Planned radioactive iodine imaging or therapy (contraindication to lipiodol)\n* Allergy to lipiodol or mitomycin\n* Allergy to iodinated contrast that cannot be treated with steroid \u002F diphenhydramine premedication\n* Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product, or that would affect subject safety","ALL","18 Years",{"count":18,"type":19},30,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","This phase II trial evaluates how well transarterial chemoembolization (TACE) works for treating patients with non-small cell lung cancer or lung metastases. TACE is a minimally invasive procedure that involves injecting chemotherapy directly into an artery that supplies blood to tumors, and then blocking off the blood supply to the tumors. Mitomycin (chemotherapy), Lipiodol (drug carrier), and Embospheres (small plastic beads that block off the artery) are injected into the tumor-feeding artery. This traps the chemotherapy inside the tumor and also cuts off the tumor\\'s blood supply. As a result, the tumor is exposed to a high dose of chemotherapy, and is also deprived of nutrients and oxygen. TACE can be effective at controlling or stopping the growth of lung tumors.",[25,26,27,28,29,30,31],"Lung Non-Small Cell Carcinoma","Mediastinal Neoplasm","Pleural Neoplasm","Lung Metastases From Any Primary","Endobronchial Metastases","Colon Cancer","Sarcoma","RECRUITING","2026-03-03",{"date":35,"type":36},"2026-03-05","ACTUAL",{"date":38,"type":36},"2023-05-12",{"date":40,"type":19},"2027-10-28",{"name":42,"class":43},"City of Hope Medical Center","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":15,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":20,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":76},"100568322","transbroncheal-novel-pdt-peripheral-lung-tumor-ablation-with-5-ala-100568322","NCT06679712","Transbroncheal Novel PDT Peripheral Lung Tumor Ablation With 5-ALA","Development of 5-Aminolevulinic Acid (5-ALA) Based Novel Tranbroncheal Photodynamic Ablation for Peripheral Lung Malignant Tumors","5ALA-TBPDT","Inclusion Criteria:\n\n* Patients with a pathological diagnosis of malignant lung tumors (including primary lung cancer and metastatic lung cancer) in advanced or terminal stages.\n* Patients for whom first- or second-line standard treatments (surgery, radiation therapy, or chemotherapy\u002Fimmunotherapy\u002Ftargeted therapy) have failed or who are unsuitable for standard treatments.\n* Tumor size of less than or equal to 3 cm, clearly visible and assessable on chest CT scans.\n* Patients whose tumors are inoperable or for whom surgery is not suitable.\n* Patients in good physical condition with an ECOG (Eastern Cooperative - -Oncology Group) performance status score of 0 to 2.\n* Patients capable of providing informed consent and willing to undergo regular follow-up during the trial.\n\nExclusion Criteria:\n\n* Diagnosis of small cell lung cancer or non-solid malignancy.\n* Tumor located in the central part of the lung.\n* Previous radiation therapy to the area intended for treatment.\n* Abnormal blood chemistry values.\n* Chemotherapy within the past 4 weeks.\n* Tumor invasion into major blood vessels.\n* Allergy to porphyrins, porphyrin-related metabolites, Lipiodol, or iodine-based contrast agents.\n* Plans to undergo curative surgery for lung tumors within the next 90 days.\n* Patients with ophthalmologic diseases who may require a slit-lamp eye examination within the next 30 days.\n* Mental illness that prevents the patient from undergoing bronchoscopy.\n* Pregnant or planning to become pregnant, breastfeeding, or planning to breastfeed within 6 months after the procedure.\n* Photodynamic therapy within the past month.\n* Severe kidney or liver disease with abnormal renal or hepatic function.\n* Plans to participate in another cancer treatment clinical trial within 3 months post-procedure.\n* Patients with AIDS.\n* Patients deemed unsuitable for the trial by the principal investigator or safety monitoring committee due to severe illness.","20 Years","75 Years",{"count":55,"type":19},6,[57],"NA","Photodynamic therapy (PDT) involves the use of special light-sensitive drugs that are selectively absorbed by cancer cells. When exposed to a specific wavelength of light, these drugs are activated within the tumor cells, triggering a free radical reaction that destroys the cancer cells. Currently, PDT is used in the treatment of early-stage lung cancer in the central airways or for advanced tumors causing airway obstruction. With advancements in medical technology, electromagnetic navigation bronchoscopy (EMB) can now be employed in a hybrid operating room (Hybrid OR) under radiological guidance to direct photodynamic therapy fibers to the tumor site for light therapy.\n\nOur research team previously proposed a novel light transmission method, using Sodium Porfimer as the photosensitizer. In the Hybrid OR, electromagnetic navigation bronchoscopy was utilized to infuse Lipiodol into the bronchial tree, enhancing the illumination range through the optical fiber effect. Energy of 630 nm at 200 J\u002Fcm (400 mW\u002F500 seconds) delivered through a 3 cm cylindrical laser fiber was deemed safe, with no significant acute complications observed. However, due to the low light dosage, the therapeutic outcome was suboptimal, although one case demonstrated tumor necrosis with no apparent damage to the surrounding lung tissue. A second-phase pilot clinical trial aimed at improving light energy and treatment coverage through a multi-session, multi-angle light exposure model is also proved this method is feasible and safe.\n\nIn addition to Sodium Porfimer, other photosensitizers are approved for clinical use in photodynamic diagnosis and therapy. For example, 5-Aminolevulinic Acid (5-ALA) has been approved for the treatment of brain cancer surgery. Similar to Sodium Porfimer, 5-ALA is a precursor of heme, and in certain cells (such as cancer cells and reticuloendothelial tissues) where there is a deficiency of the enzyme ferrochelatase, administering large amounts of 5-ALA or Sodium Porfimer leads to the accumulation of Protoporphyrin IX (PpIX). PpIX is a photosensitizer, and when exposed to a specific wavelength of light, it generates oxygen free radicals that destroy cancer cells, thereby producing the therapeutic effect of PDT.\n\nWe propose this clinical trial to explore the use of 5-ALA as a substitute for Sodium Porfimer in the novel PDT treatment of peripheral lung tumors. Compared to Sodium Porfimer, 5-ALA has the same therapeutic mechanism but a shorter half-life. It can be taken orally 2-4 hours before treatment, requires only one day of light protection post-procedure, and is more cost-effective. 5-ALA (Gliolan) has also been approved by the FDA for photodynamic diagnosis and treatment of brain cancer, and clinical trials in other cancers have demonstrated its safety and feasibility.\n\nThis phase 0 pilot clinical study plans to recruit six patients with peripheral malignant lung tumors (tumor diameter ≤ 30 mm). 5-ALA (Gliolan) will be used as the photosensitizer, and in the hybrid operating room, electromagnetic navigation bronchoscopy will guide a catheter to the tumor site. Lipiodol (iodized poppy seed oil) will be infused to coat the tumor, enhancing the light exposure range. The first three subjects will undergo a single-session light exposure to assess the feasibility and safety of the procedure. The remaining three subjects will receive multi-session, multi-angle light exposure to further verify the safety and effectiveness of the treatment. The findings from these subjects will serve as a reference for light energy parameters for future phase I clinical trials.",[60,28],"Lung Cancer - Non Small Cell",[62,63,64],"Photodynamic therapy","Peripheral lung cancer","Transbroncheal Ablation","NOT_YET_RECRUITING","2024-11-06",{"date":68,"type":36},"2024-11-07",{"date":70,"type":19},"2024-12-01",{"date":72,"type":19},"2026-12-31",{"name":74,"class":75},"Taoyuan General Hospital","OTHER_GOV",1]